HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
Environmental, Social and Governance (ESG) Policy
IR Contacts
Latest News
Oct
16
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME
Oct
15
VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME
Oct
15
VOLUNTARY ANNOUNCEMENT - SYS6088 INJECTION (A TRI-SPECIFIC ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2026 Interim Report
Highlight - 2026 Interim Results
Revenue
RMB18,594M, +40.1%
Reported profit attributable to shareholders of the Company
RMB6,094M, +139.2%
Underlying profit attributable to shareholders of the Company
RMB6,164M, +165.8%
Basic earnings per share (based on reported profit attributable to shareholders of the Company)
RMB53.45 cents, +139.8%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine